fbpx Skip to main content


Sylvie Laquerre, Ph.D.



Sylvie Laquerre, Ph.D., is Vice President, Solid Tumor Targeted Therapies Disease Area Stronghold Leader in the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, Sylvie is responsible for the strategic direction and execution of the Solid Tumor Disease Area portfolio, from early drug discovery efforts through clinical development.

Upon joining Janssen in 2013, Sylvie contributed to the approval of a novel treatment for patients with metastatic urothelial cancer; and identified, validated and advanced multiple small and large molecule candidates from discovery to the clinic. Additionally, Sylvie built a strong pre-clinical portfolio of targeted solid tumor driver pathway and immunotherapy agents. In her most recent role, Sylvie led the global discovery Solid Tumor Drug Discovery Cancer Disease Area Stronghold, Oncology Therapeutic Area where she was responsible for the strategic direction and execution of the discovery portfolio for the solid tumor disease area from target validation to clinical proof-of-concept.

Prior to joining Janssen, Sylvie led multiple programs at GSK in obesity, IBS and fibrosis and brought multiple oncology assets to the clinic and on to FDA approval (dabrafenib and trametinib). Prior to joining GSK, Sylvie led a team at ViroPharma Inc. where she developed anti-viral agents, one of which was stock-piled by the USA National Defense Department in response to potential bioterrorism warfare. Early in her career as a Senior Scientist with Onyx Pharmaceutical, Sylvie led the HSV oncolytic virus effort and armed replication competent adenovirus with replication dependent cancer suicide genes.

Sylvie received her Ph.D. from Laval University, Canada, in Molecular and Cellular Biology studying calmodulin involvement in the cell cycle. She conducted her post-doctoral fellowship at the University of Pittsburgh, PA on HSV targeted therapy where she continued as a Senior Staff Fellow. Sylvie has published extensively in oncology, gene therapy and has experience in multiple drug modalities with successful drug discovery research leading to FDA approval.